DATA GRAPHICS | Data Byte
New targets at AACR 2022
Companies are presenting at least 44 targets not yet addressed by disclosed clinical or preclinical programs
April 9, 2022 12:09 AM UTC
T cells and other immune mediators continue to be major sources of new therapeutic targets at this year’s AACR meeting, with stress and damage repair pathways making a strong showing as well.
BioCentury’s analysis of the abstracts presented at the American Association for Cancer Research (AACR) annual meeting identifies 44 new targets that aren’t addressed by any cancer programs in clinical or preclinical development, according to BioCentury’s BCIQ database. ...